Biotech venture capital funding surged in the first half of 2026, reaching $9.1 billion—its highest since early 2022. Key factors included strong public market performance and increased deal activity, with 76% of funds raised from larger financing rounds over $100 million. Notably, 13 biotech firms collectively raised $4.5 billion in IPO proceeds, with many trading above their initial prices.
However, the market remains cautious. Earlier rounds, especially for seed-stage startups and first-time founders, are not as plentiful as in the past, and much funding is going to firms with drug prospects already in human testing. Concerns persist about future early innovation due to reduced research funding at institutions like the NIH.
Investment trends show a preference for cancer and immune drugmakers, while cellular and genetic medicine sectors continue to face challenges, potentially raising around $2 billion in 2026, similar to previous years. Regulatory scrutiny and market performance issues are making investors hesitant in these areas, impacting future capital allocations.
